JP7222236B2 - oral solid composition - Google Patents

Description

The present invention relates to oral solid compositions.

In general, the active ingredient in a pharmaceutical preparation accounts for about 1% to 20% of the weight of the preparation, and the rest of the ingredients are diluted with additives such as excipients. Processing has traditionally been devised to achieve uniform content among unit dosage forms. For example, when producing tablets, it has long been practiced to prepare granules and then tablet them. However, it is also known that, especially in low-content preparations with an active ingredient content of less than 1% in the weight of the preparation, it is difficult to achieve a uniform content even if the tablets are produced after the granules are produced because of the small amount of the active ingredient. .

Under such a background, Patent Literature 1 proposes a method of miniaturizing an active ingredient. However, some active ingredients have poor physical properties and may cause high adhesion loss due to static electricity or moisture absorption. Also, the active ingredient is limited to entecavir.

In Patent Document 2, 2-methyl-2-[4-{[(4-methyl-2-[4-trifluoromethylphenyl]-thiazol-5-ylcarbonyl)amino]methyl}phenoxy is used as a specific active ingredient. ] There are proposals for low-dose formulations of propionic acid (less than 100 μg). It may be an effective technique for this active ingredient, but it is widely known that the physical properties of granules differ depending on the active ingredient, and it cannot be said that the results for one active ingredient can be directly applied to other active ingredients.

In US Pat. No. 5,200,000, cellulose acetobutyrate (a type of hydrophobic polymer), which is highly soluble in dichloromethane (a water-immiscible organic solvent medium), and disodium stearoyl glutamic acid (a surfactant) are used to prepare cellulose. The preparation of 124 nm size nanocapsules containing acetobutyrate and disodium stearoyl glutamate is described (Example 3). The nanocapsules described in Patent Document 5 require the use of a water-immiscible organic solvent medium capable of dissolving a large amount of the hydrophobic polymer and a surfactant in the manufacturing process. Water-immiscible organic solvent vehicles and surfactants have the problem of skin irritation in topical applications.

In Non-Patent Document 1, repaglinide and ethyl cellulose-containing ethyl acetate (organic phase) are added dropwise to a polyvinyl alcohol (surfactant)-containing aqueous phase, treated with a high-pressure homogenizer, and then the organic phase is removed from the aqueous phase under reduced pressure. described obtaining sustained-release nanocapsules containing repaglinide and ethylcellulose.

Japanese Patent No. 6001763 Japanese Patent Publication No. 2007-532511 JP 2005-248162 A

Amolkumar B. Lokhande et al. , Journal of Pharmacy Research (2013), 7(5), 421-426

As mentioned above, although there are techniques for improving the content uniformity of low-content preparations by specializing in specific active ingredients, it is desired to develop a technique for improving the content uniformity in general without being limited to specific active ingredients. ing.

As a result of intensive studies, the present inventors prepared predetermined particles that are polymer composites containing a combination of polymers such as predetermined cellulose derivatives and active ingredients, and formulated them as pharmaceuticals to solve the above problems. We have found that the problem can be solved, and have completed the present invention.

That is, the present invention is as follows.
[1] comprising 10 or more oral solid compositions in a unit dosage form;
The oral solid composition comprises the following components (i)-(iii) and comprises particles having properties (a)-(d):
(i) one or more polymers selected from the group consisting of hydroxyalkylcellulose, carboxyalkylcellulose, cationized cellulose, and ester derivatives thereof, and salts thereof;
(ii) (ii-1) alkyl cellulose, hydroxyalkyl alkyl cellulose, hydrophobized cellulose, ester derivatives thereof, and salts thereof, and (ii-2) alkylene-based polymers and copolymers thereof, and salts thereof one or more polymers selected from the group; and (iii) an active ingredient;
(a) the active ingredient is contained inside the particle;
(b) a volume distribution average particle size of 1 to 900 nm;
(c) the particles have the property that the contact angle of water on the particle film is between 20 and 70 degrees;
(d) the particles are substantially free of surfactants;
A set of oral solid compositions, wherein the amount of active ingredient in said oral solid composition is 10% by weight or less and has a content uniformity criterion of less than 10%.
[2] The set of [1], wherein the particles have the property that the ratio of the contact angle of water on the particle film to the contact angle of water on the polystyrene substrate is within the range of 0.2 to 0.9.
[3] The set of [1] or [2], wherein the particles have the property that the absolute value of electrophoretic mobility is 2 μmcm/Vs or more.
[4] The set of any one of [1] to [3], wherein the surface of the particles is negatively charged.
[5] The set of any one of [1] to [4], wherein the particles do not substantially contain a plasticizer.
[6] The set of any one of [1] to [5], wherein the polymer (i) is one or more polymers selected from the group consisting of hydroxyalkylcellulose, carboxyalkylcellulose, and salts thereof.
[7] hydroxyalkyl cellulose is hydroxyethyl cellulose or hydroxypropyl cellulose;
The set of [6], wherein the carboxyalkyl cellulose is carboxymethyl cellulose.
[8] The polymer (ii) is one or more polymers selected from the group consisting of alkylcellulose, hydroxyalkylalkylcellulose, ester derivatives of hydroxyalkylalkylcellulose, and salts thereof, [1]- Any set of [7].
[9] the alkyl cellulose is methyl cellulose or ethyl cellulose,
hydroxyalkylalkylcellulose is hydroxypropylmethylcellulose,
The set of [8], wherein the ester derivative of hydroxyalkylalkylcellulose is hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate.
[10] the polymer (ii) is one or more polymers selected from the group consisting of alkylene-based polymers, copolymers thereof, and salts thereof;
The set according to any one of [1] to [7], wherein the alkylene-based polymer and its copolymer are selected from the group consisting of vinyl-based polymers, propylene-based polymers, butylene-based polymers, and copolymers thereof.
[11] The vinyl-based polymer is a polymer containing one or more monomer units selected from the group consisting of vinyl alcohol, acrylic acid and its ester derivatives, methacrylic acid and its ester derivatives, and vinylpyrrolidone. 10] set.
[12] The set of any one of [1] to [11], wherein the particles have a substantially uniform size.
[13] The set of any one of [1] to [12], wherein the active ingredient is a low-molecular-weight compound.
[14] The set of any one of [1] to [13], wherein the amount of active ingredient relative to the weight of the particles is 0.01 to 80% (wt).
[15] The set of any one of [1] to [14], wherein the amount of active ingredient relative to the weight of the particles is 0.1 to 15% (wt).
[16] The set of any one of [1] to [15], wherein the particles have an effect of permeating the active ingredient into living tissue.
[17] The set of [16], wherein the living tissue is skin.
[18] The set of [16], wherein the living tissue is stratum corneum.
[19] The set of any one of [1] to [18], wherein the active ingredient is a pharmaceutical ingredient and the oral solid composition is a pharmaceutical.
[20] The oral solid composition is tablet, capsule, granule, powder, fine granule, dry syrup, cashew, pill, drop, troche, gum, chocolate, or gummies [1] to [19] any set of

According to oral solid compositions, content uniformity can be improved for general purposes without being limited to specific active ingredients.

FIG. 1 is a view showing a scanning electron micrograph of particles obtained in Reference Example 1 (see Reference Example 1). FIG. 2 is a scanning electron micrograph of the particles prepared in Reference Example 3 after air drying (see Reference Test Example 3).

The present invention relates to a set of oral solid compositions comprising 10 or more oral solid compositions in unit dosage form.

The oral solid composition included in the set of the present invention comprises particles (hereinafter, optionally referred to as "particles") that include components (i) to (iii) below and have properties (a) to (d). ) including:
(i) one or more polymers selected from the group consisting of hydroxyalkylcellulose, carboxyalkylcellulose, cationized cellulose, and ester derivatives thereof, and salts thereof;
(ii) (ii-1) alkyl cellulose, hydroxyalkyl alkyl cellulose, hydrophobized cellulose, ester derivatives thereof, and salts thereof, and (ii-2) alkylene-based polymers and copolymers thereof, and salts thereof one or more polymers selected from the group; and (iii) an active ingredient;
(a) the active ingredient is contained inside the particle;
(b) a volume distribution average particle size of 1 to 900 nm;
(c) the particles have the property that the contact angle of water on the particle film is between 20 and 70 degrees;
(d) the particles are substantially free of surfactants;

1. Particle The particle comprises (i) one or more polymers selected from the group consisting of hydroxyalkylcellulose, carboxyalkylcellulose, cationized cellulose, ester derivatives thereof, and salts thereof, and (ii) (ii-1) One or more selected from the group consisting of alkyl cellulose, hydroxyalkyl alkyl cellulose, hydrophobized cellulose, ester derivatives thereof, salts thereof, and (ii-2) alkylene-based polymers and copolymers thereof, and salts thereof It is a mixture with a polymer.

The polymer contained in the particles is not particularly limited as long as it has any weight-average molecular weight that can stabilize the morphology of the particles. or more, and more preferably 40,000 or more. The weight average molecular weight is also, from the viewpoint of availability of materials, for example, 1,000,000 or less, 800,000 or less, 600,000 or less, 400,000 or less, 300,000 or less, or 200,000 It may be below.

Alkyl in hydroxyalkyl cellulose, carboxyalkyl cellulose, and alkyl cellulose is the same as alkyl which is an example of a monovalent hydrocarbon group described later, and the preferred range is also the same. The two alkyl groups in the hydroxyalkylalkyl cellulose may be the same or different, and are the same as the alkyls that are examples of the above monovalent hydrocarbon groups, and the preferred ranges are also the same.

Hydroxyalkyl celluloses include, for example, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxybutyl cellulose, hydroxypentyl cellulose, and hydroxyhexyl cellulose. Preferably, the hydroxyalkyl cellulose is hydroxyethyl cellulose, hydroxypropyl cellulose.

Carboxyalkyl celluloses include, for example, carboxymethyl cellulose, carboxyethyl cellulose, carboxypropyl cellulose, carboxybutyl cellulose, carboxypentyl cellulose, and carboxyhexyl cellulose. Preferably, the carboxyalkylcellulose is carboxymethylcellulose.

Alkyl celluloses include, for example, methyl cellulose, ethyl cellulose, propyl cellulose, butyl cellulose, pentyl cellulose, and hexyl cellulose. Preferably, the alkyl cellulose is methyl cellulose, ethyl cellulose.

Hydroxyalkylalkylcellulose is cellulose with both hydroxyalkyl and alkyl. Examples of hydroxyalkylalkylcelluloses include celluloses having hydroxymethyl and alkyl (e.g., hydroxymethylmethylcellulose, hydroxymethylethylcellulose, hydroxymethylpropylcellulose, hydroxymethylbutylcellulose), celluloses having hydroxyethyl and alkyl (e.g., hydroxyethyl methylcellulose, hydroxyethylethylcellulose, hydroxyethylpropylcellulose, hydroxyethylbutylcellulose), celluloses with hydroxypropyl and alkyl (e.g., hydroxypropylmethylcellulose (hypromellose), hydroxypropylethylcellulose, hydroxypropylpropylcellulose, hydroxypropylbutylcellulose), Celluloses with hydroxybutyl and alkyl (eg, hydroxybutylmethylcellulose, hydroxybutylethylcellulose, hydroxybutylpropylcellulose, and hydroxybutylbutylcellulose) are included. Preferably, the hydroxyalkylalkylcellulose is hydroxypropylmethylcellulose (hypromellose).

Cationized cellulose refers to cellulose having a cationic group or a cellulose derivative having a cationic group. Cationic groups include, for example, trialkylammonium. The three alkyls in the trialkylammonium may be the same or different, and are the same as the alkyls described later, and the preferred ranges are also the same.

Hydrophobized cellulose refers to cellulose having a hydrophobic group or a cellulose derivative having a hydrophobic group. Hydrophobized cellulose includes, for example, acetylated cellulose.

In the ester derivative, the hydrogen atom in the hydroxy in the cellulose derivative is substituted with R—C(═O)—(R represents an optionally substituted monovalent hydrocarbon group.) to form an ester moiety. It is a derivative that forms The monovalent hydrocarbon group represented by R is the same as the "monovalent hydrocarbon group" in the "monovalent hydrocarbon group optionally having a substituent" described later, and the preferred range is also It is the same. The number of carbon atoms in the monovalent hydrocarbon group does not include the number of carbon atoms in the substituent. When the monovalent hydrocarbon group is substituted, the substituent is the same as the secondary substituent described later, and the preferred range is also the same.

The "monovalent hydrocarbon group" in the "optionally substituted monovalent hydrocarbon group" includes, for example, a monovalent chain hydrocarbon group, a monovalent alicyclic hydrocarbon group, and monovalent aromatic hydrocarbon groups.

A monovalent chain hydrocarbon group means a hydrocarbon group composed only of a chain structure, and the main chain does not contain a cyclic structure. However, the chain structure may be linear or branched. Examples of monovalent chain hydrocarbon groups include alkyl, alkenyl, and alkynyl. Alkyl, alkenyl and alkynyl can be straight or branched.
The alkyl is preferably an alkyl having 1 to 12 carbon atoms, more preferably an alkyl having 1 to 6 carbon atoms, and still more preferably an alkyl having 1 to 4 carbon atoms. The above number of carbon atoms does not include the number of carbon atoms of substituents. Examples of alkyl having 1 to 12 carbon atoms include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, isobutyl, t-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl. , dodecyl.
Alkenyl is preferably alkenyl having 2 to 12 carbon atoms, more preferably alkenyl having 2 to 6 carbon atoms, and even more preferably alkenyl having 2 to 4 carbon atoms. The above number of carbon atoms does not include the number of carbon atoms of substituents. Examples of alkenyl having 2 to 12 carbon atoms include vinyl, propenyl and n-butenyl.
Alkynyl is preferably alkynyl having 2 to 12 carbon atoms, more preferably alkynyl having 2 to 6 carbon atoms, and even more preferably alkynyl having 2 to 4 carbon atoms. The above number of carbon atoms does not include the number of carbon atoms of substituents. Examples of alkynyl having 2 to 12 carbon atoms include ethynyl, propynyl and n-butynyl.
Alkyl is preferred as the monovalent chain hydrocarbon group.

A monovalent alicyclic hydrocarbon group means a hydrocarbon group that contains only an alicyclic hydrocarbon as a ring structure and does not contain an aromatic ring. may be However, it does not have to be composed only of alicyclic hydrocarbons, and may partially contain a chain structure. Examples of monovalent alicyclic hydrocarbon groups include cycloalkyl, cycloalkenyl, and cycloalkynyl, which may be either monocyclic or polycyclic.
As cycloalkyl, cycloalkyl having 3 to 12 carbon atoms is preferable, cycloalkyl having 3 to 6 carbon atoms is more preferable, and cycloalkyl having 5 to 6 carbon atoms is even more preferable. The above number of carbon atoms does not include the number of carbon atoms of substituents. Examples of cycloalkyl having 3 to 12 carbon atoms include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
As cycloalkenyl, cycloalkenyl having 3 to 12 carbon atoms is preferable, cycloalkenyl having 3 to 6 carbon atoms is more preferable, and cycloalkenyl having 5 to 6 carbon atoms is even more preferable. The above number of carbon atoms does not include the number of carbon atoms of substituents. Cycloalkenyl having 3 to 12 carbon atoms includes, for example, cyclopropenyl, cyclobutenyl, cyclopentenyl and cyclohexenyl.
As cycloalkynyl, cycloalkynyl having 3 to 12 carbon atoms is preferable, cycloalkynyl having 3 to 6 carbon atoms is more preferable, and cycloalkynyl having 5 to 6 carbon atoms is even more preferable. The above number of carbon atoms does not include the number of carbon atoms of substituents. Cycloalkynyl having 3 to 12 carbon atoms includes, for example, cyclopropynyl, cyclobutynyl, cyclopentynyl and cyclohexynyl.
Cycloalkyl is preferred as the monovalent alicyclic hydrocarbon group.

A monovalent aromatic hydrocarbon group means a hydrocarbon group containing an aromatic ring structure. However, it does not have to be composed only of aromatic rings, and may contain a chain structure or alicyclic hydrocarbon in part, and the aromatic ring may be monocyclic or polycyclic. good. The monovalent aromatic hydrocarbon group is preferably an aryl having 6 to 12 carbon atoms, more preferably an aryl having 6 to 10 carbon atoms, and still more preferably an aryl having 6 carbon atoms. The above number of carbon atoms does not include the number of carbon atoms of substituents. Examples of aryl having 6 to 12 carbon atoms include phenyl and naphthyl.
Phenyl is preferred as the monovalent aromatic hydrocarbon group.

Among these, the monovalent hydrocarbon group is preferably alkyl, cycloalkyl or aryl, more preferably alkyl.

When the "monovalent hydrocarbon group" has a substituent, a hydrogen atom in the "monovalent hydrocarbon group" is substituted. The number of substituents in the "monovalent hydrocarbon group" is 1 to 5, preferably 1 to 3, more preferably 1 or 2.

Substituents (also referred to as secondary substituents) that the "monovalent hydrocarbon group" may have include, for example, halogen atoms (e.g., fluorine atom, chlorine atom, bromine atom, iodine atom), carboxy, sulfo, cyano, nitro, mercapto, oxo, guanidino, hydroxy, alkyl, alkyloxy, alkylcarbonyl, alkyloxycarbonyl, alkylcarbonyloxy, amino optionally mono- or di-substituted with alkyl (e.g., amino), and amino-carbonyl (eg, amido) optionally mono- or di-substituted with alkyl. "Alkyl" in alkyl, alkyloxy, alkylcarbonyl, alkyloxycarbonyl, alkylcarbonyloxy, amino optionally mono- or di-substituted with alkyl, and amino-carbonyl optionally mono- or di-substituted with alkyl is It is the same as alkyl, which is an example of the above monovalent hydrocarbon group, and the preferred range is also the same.

Preferably, the ester moiety of the above ester derivative is one or more (eg, one or two) ester moieties selected from the group consisting of phthalate, acetate, and succinate.

In a preferred embodiment, the ester derivative is an ester derivative of alkylcellulose or hydroxyalkylalkylcellulose. In a more preferred embodiment, the ester derivative is an ester derivative of hydroxyalkylalkylcellulose. Ester derivatives of hydroxyalkylalkylcellulose include, for example, hydroxypropylmethylcellulose phthalate and hydroxypropylmethylcellulose acetate succinate.

The alkylene-based polymer refers to an alkylene polymer in which some or all of the alkylene monomer units have substituents. For example, if alkylene is vinyl, vinyl polymers include vinyl polymers having substituents, but do not include vinyl polymers having no substituents. In alkylene-based polymers, hydrogen atoms in alkylene are substituted with substituents. The number of substituents in alkylene is 1 to 5, preferably 1 to 3, more preferably 1 or 2.

As alkylene, alkylene having 1 to 12 carbon atoms is preferable, alkylene having 1 to 6 carbon atoms is more preferable, and alkylene having 1 to 4 carbon atoms is particularly preferable. The above number of carbon atoms does not include the number of carbon atoms of substituents. Alkylene may be linear, branched or cyclic, but linear alkylene is preferred. Such alkylenes include, for example, methylene, ethylene, propylene, butylene, pentylene, hexylene.

In certain embodiments, alkylene-based polymers include halogen atoms (e.g., fluorine atoms, chlorine atoms, bromine atoms, iodine atoms), carboxy, sulfo, cyano, nitro, mercapto, oxo, guanidino, hydroxy, alkyl, alkyloxy, from alkylcarbonyl, alkyloxycarbonyl, alkylcarbonyloxy, amino optionally mono- or di-substituted with alkyl (eg amino), and amino-carbonyl optionally mono- or di-substituted with alkyl (eg amido) It is an alkylene polymer having 1 to 5, preferably 1 to 3, more preferably 1 or 2 substituents selected from the group consisting of: "Alkyl" in alkyl, alkyloxy, alkylcarbonyl, alkyloxycarbonyl, alkylcarbonyloxy, amino optionally mono- or di-substituted with alkyl, and amino-carbonyl optionally mono- or di-substituted with alkyl is It is the same as alkyl, which is an example of the above monovalent hydrocarbon group, and the preferred range is also the same.

The alkylene-based polymer is preferably a vinyl (ethylene)-based polymer, a propylene-based polymer, a butylene-based polymer, or a copolymer thereof, or a salt thereof, and a vinyl-based polymer, a propylene-based polymer, a copolymer thereof, or a salt thereof. is preferred, and a vinyl polymer or a salt thereof is more preferred. Examples of vinyl-based polymers include polymers containing one or more monomer units selected from the group consisting of vinyl alcohol, acrylic acid or its ester derivatives, methacrylic acid or its ester derivatives, and vinylpyrrolidone. Preferably, the vinyl-based polymer may be polyvinyl alcohol, polyacrylic acid or its ester derivative, polymethacrylic acid or its ester derivative, polyvinylpyrrolidone.

Copolymers of alkylene-based polymers are polymers composed of two or more of the above-described alkylene-based polymers.

Salts include, for example, metal salts, acid addition salts, and salts with bases. Metal salts include, for example, salts with monovalent metals (eg, sodium and potassium) and salts with divalent metals (eg, calcium and magnesium). Acid addition salts include, for example, salts with inorganic acids (e.g., hydrogen chloride, hydrogen bromide, sulfuric acid, and phosphoric acid), and organic acids (e.g., acetic acid, lactic acid, citric acid, tartaric acid, maleic acid, fumaric acid). , and monomethyl sulfate). Examples of salts with bases include salts with inorganic bases (e.g., ammonia) and salts with organic bases (e.g., ethylenediamine, propylenediamine, ethanolamine, monoalkylethanolamine, dialkylethanolamine, diethanolamine, triethanolamine). salt of As the salt, a metal salt is preferred.

The particles comprise mixtures of two or more polymers as described above. By containing a mixture of two or more of the above polymers, there is an advantage that the particle surface can be imparted with an appropriate level of hydrophobicity while having a hydrophilic site that is compatible with a hydrophilic substance inside the particle. Preferably, the mixture of two or more polymers mentioned above is a mixture of two or more (eg 2, 3, 4 or 5) polymers comprising a hydrophilic polymer and a hydrophobic polymer.

In the present invention, a hydrophilic polymer refers to a polymer having a solubility of 1% (wt) or more in an aqueous solution (preferably water). As the solubility, the solubility at normal temperature (eg, 15 to 25°C) is preferable, and the solubility at 20°C is more preferable. For water-soluble polymers, the solubility in an aqueous solution (preferably water) is preferably 5% (wt) or more, more preferably 7% (wt) or more. The hydrophilic polymer is an anionic hydrophilic polymer, a nonionic hydrophilic polymer or a cationic hydrophilic polymer, preferably an anionic hydrophilic polymer or a nonionic hydrophilic polymer. Specific examples of hydrophilic polymers include hydroxyalkylcellulose, carboxyalkylcellulose, cationized cellulose, and ester derivatives thereof, and salts thereof, including hydroxyalkylcellulose, hydroxycellulose, carboxyalkylcellulose, carboxycellulose, and Ester derivatives thereof and salts thereof are preferred, hydroxyalkylcelluloses, carboxyalkylcelluloses and ester derivatives thereof and salts thereof are more preferred, and hydroxyalkylcelluloses, carboxyalkylcelluloses and salts thereof are even more preferred. , hydroxyalkylcelluloses, and salts thereof are particularly preferred.

Preferably, the hydrophilic polymer may be a hydrophilic polymer (amphiphilic polymer) that easily migrates to an organic solvent. An amphipathic polymer is a polymer that has an aggregation site consisting of a hydrophilic functional group and an aggregation site consisting of a hydrophobic functional group in one molecule, and forms a polymer micelle at the water-oil interface like a surfactant. say. The amphiphilic polymer is an anionic amphiphilic polymer, a nonionic amphiphilic polymer or a cationic amphiphilic polymer, with an anionic amphiphilic polymer or a nonionic amphiphilic polymer being preferred. Specific examples of amphiphilic polymers include hydroxyalkylcelluloses, carboxyalkylcelluloses, cationized celluloses, and ester derivatives thereof, and salts thereof, including hydroxyalkylcelluloses, carboxyalkylcelluloses, and ester derivatives thereof; and salts thereof are preferred, hydroxyalkylcelluloses, carboxyalkylcelluloses and salts thereof are more preferred, and hydroxyalkylcelluloses and salts thereof are even more preferred.

For purposes of the present invention, a hydrophobic polymer refers to a polymer that has a solubility of less than 1% (wt) in an aqueous solution (preferably water). As the solubility, the solubility at normal temperature (eg, 15 to 25°C) is preferable, and the solubility at 20°C is more preferable. For water-soluble polymers, the solubility in an aqueous solution (preferably water) is preferably 0.1% (wt) or less, more preferably 0.01% (wt) or less.

Preferably, specific examples of hydrophobic polymers include alkylcelluloses, hydroxyalkylalkylcelluloses, hydrophobized celluloses, their ester derivatives, and their salts; vinyl (ethylene)-based polymers, propylene-based polymers, and butylene system polymers, as well as copolymers thereof.

The active ingredient is contained inside the particles. It has been confirmed that the active ingredient is contained in the particles even after multiple washings of the particles with the solution. The active ingredient contained in the particles is the ingredient that is not covalently bound to the polymer and is free from the polymer. Active ingredients include, for example, low-molecular-weight compounds, polysaccharides, peptides, oligopeptides, polypeptides (e.g., enzymes, ligands, antibodies, extracellular matrix proteins), polysaccharides, polynucleotides (e.g., DNA, RNA, artificial nucleic acids). ), oligonucleotides (eg, oligoDNA, oligoRNA, oligonucleic acid). The term "low molecular weight compound" refers to a compound having a molecular weight of 1500 or less. Small compounds are natural or synthetic compounds. The molecular weight of the low molecular compound may be 1200 or less, 1000 or less, 900 or less, 800 or less, 700 or less, 600 or less, 500 or less, 400 or less, or 300 or less. The molecular weight of the small molecule compound may also be 30 or greater, 40 or greater, or 50 or greater. Low-molecular-weight compounds include, for example, amino acids, vitamins, nucleosides, nucleotides, oligonucleotides, monosaccharides, opioids, lipids, fatty acids, metabolites thereof, and salts thereof (e.g., metal salts as described above, acid addition a salt, or a salt with a base (the same shall apply hereinafter). Active ingredients also include pharmaceutical ingredients (e.g., therapeutic agents, preventive agents), ingredients for quasi-drugs (e.g., whitening ingredients, anti-wrinkle ingredients, rough skin improvement ingredients, hair growth ingredients), cosmetic ingredients (e.g., glycerin, etc.). alcohols, oils, extracts), food ingredients (eg nutritional ingredients), diagnostic ingredients (eg contrast agents), hair care ingredients (eg coloring agents), nail polish ingredients. The active ingredients contained in the particles may be of one type, or may be a mixture of two or more types. The active ingredient can exist dispersed in a solution (aqueous solution or organic solvent) within the polymer particles. The particles may also contain other ingredients such as additives (eg, preservatives such as methylparaben, antioxidants) in addition to the active ingredient.

The active ingredient may be a water-soluble ingredient or a hydrophobic ingredient. A water-soluble component as an active ingredient is a component that dissolves more easily in an aqueous solution (preferably water) than in an organic solvent used in the method for producing particles described below. A hydrophobic component as an active ingredient is a component that dissolves more easily in an organic solvent than in an aqueous solution (preferably water) used in the method for producing particles described below.

In preferred embodiments, the active ingredient is an amino acid, or salt thereof. Examples of amino acids include α-amino acids (e.g., alanine, asparagine, cysteine, glutamine, isoleucine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, aspartic acid, glutamic acid, arginine, histidine, lysine, , glycine), β-amino acids (eg, β-alanine, pantothenic acid), γ-amino acids (eg, γ-aminobutyric acid), δ-amino acids, ε-amino acids (eg, tranexamic acid). Amino acids may be in the L- or D-configuration.

In another preferred embodiment, the active ingredient is an oligopeptide, or salt thereof. Oligopeptides include, for example, dipeptides (eg, glutamyllysine, γ-glutamylcysteine), tripeptides (eg, glutamylvalylglycine, glutathione), tetrapeptides (eg, capixyl), and pentapeptides (eg, leuphacil). . Amino acids constituting an oligopeptide may be in the L-form or the D-form.

In yet another preferred embodiment, the active ingredient is a water-soluble or fat-soluble vitamin, or salt thereof. Water-soluble vitamins include, for example, vitamin B, vitamin C, and derivatives thereof. Examples of vitamin B include vitamin B1 (thiamine), vitamin B2 (riboflavin), vitamin B3 (eg, niacin, nicotinamide), vitamin B5 (eg, pantothenic acid, dexpanthenol, pantethine), vitamin B6 (eg, pyridoxine, pyridoxal phosphate, pyridoxamine), vitamin B7 (biotin), vitamin B9 (eg, folic acid, dihydrofolic acid, folinic acid), vitamin B12 (eg, cyanocobalamin, hydroxocobalamin, methylcobalamin, cobamamide). Vitamin B derivatives include, for example, thiamine disulfide, benfotiamine, fursultiamine. Vitamin C includes, for example, ascorbic acid and dehydroascorbic acid. Examples of vitamin C derivatives include ascorbic acid 2-glucoside (AA-2G), ascorbic acid phosphate, ethyl ascorbyl, ascopyrmagnesium phosphate, trisodium ascopylate phosphate, and ascobyl tetraisopalmitate (VC-IP). be done. Fat-soluble vitamins include, for example, vitamin D, vitamin E, vitamin K, vitamin A, and derivatives thereof.

In another preferred embodiment, other active ingredients include, for example, whitening ingredients (e.g., cysteine, vitamin C, vitamin C derivatives, tranexamic acid, arbutin, ceramide, kojic acid, ellagic acid), anti-wrinkle ingredients (e.g., ceramide), moisturizing ingredients (e.g. pyrrolidone carboxylic acid, 3-acetyl-2-ethoxycarbonyl-2-methyl-1,3-thiazolidine-4-carboxylate Na), hair growth ingredients (e.g. minoxidil), metabolism improving ingredients ( (eg, dihydroxycapsiate), and salts thereof.

In yet another preferred embodiment, the active ingredient may be a medicament.

Since the ratio of the weight of the active ingredient to the weight of the particles (the total weight of the polymer and active ingredients that make up the particles) varies depending on the type of the polymer that makes up the particles and the active ingredient, and the conditions of the method for preparing the particles, Although it is not particularly limited, it is, for example, 0.01 to 80%. The ratio of the weight of active ingredient to the weight of the particles is preferably 0.05-40%, more preferably 0.1-15%, even more preferably 0.2-14%, particularly preferably 0.5-12%. % or 1.0-10%. Alternatively, the concentration of active ingredient in the interior of the particles is, for example, 0.01-50% (wt), preferably 0.02-40% (wt), more preferably 0.05-30% (wt), even more Preferably, it may be from 0.1 to 20% (wt).
Determination of the weight of active ingredient can be done by any method known in the art. Such methods include, for example, methods using high performance liquid chromatography (HPLC) and spectrophotometers (eg, UV-VIS spectrophotometers). The concentration of the active ingredient can also be estimated from the concentration of the active ingredient in the aqueous solution containing the active ingredient, or the aqueous solution containing both the active ingredient and the second polymer, used in the preparation of the particles.

The particles may also contain certain components such as surfactants (e.g. sorbitan monooleate), residual organic solvents (e.g. hydrocarbon compounds such as hexane), plasticizers (e.g. component) may be substantially free. Contamination of these components can be avoided because the particles do not inherently require the use of these components in their manufacturing process. In terms of particles, the expression "substantially free" means that the particles are completely free of the specified component, or even if the particle contains the specified component in an amount of 3.0% (wt) or less. means to contain Preferably, the expression "substantially free" means "completely free". With respect to the expression "substantially free", the particles, when containing the given component, are preferably no more than 2.0% (wt), more preferably no more than 1.5% (wt), even more preferably 1.0% (wt) or less, particularly preferably 0.5% (wt) or less, 0.4% (wt) or less, 0.3% (wt) or less, 0.2% (wt) or 0.1 % (wt) or less. More specifically, the particles are preferably substantially free of one of surfactants and residual organic solvents, and more preferably substantially free of both surfactants and residual organic solvents.

The particles can also be prepared by using acetone, an alcohol (eg, methanol), or an acetone-alcohol mixture, which may be rich in acetone, as the preferred organic solvent, as described below. Thus, the particles may be substantially free of organic solvents other than acetone, alcohol, or acetone-alcohol mixtures. Although such particles can be produced according to the method for producing particles, conventional methods for producing particles generally cannot produce such particles.

The particles may contain other ingredients in addition to the active ingredient. Other ingredients include, for example, active ingredient stabilizers (eg, antioxidants), surfactants, dispersants, and antifoaming agents.

The particles have a volume distribution average particle size of 1-900 nm. The volume distribution average particle size is preferably 5 nm or more, more preferably 10 nm or more, still more preferably 20 nm or more, or 50 nm or more. The volume distribution average particle size is also preferably 850 nm or less, more preferably 800 nm or less.
The volume distribution average particle size can be measured by measuring the particle size distribution by laser diffraction. Preferably, the measurement of the particle size distribution by the laser diffraction method can be performed using a laser diffraction particle size distribution analyzer (ZetasizerNanoS manufactured by Malvern Instruments Ltd.).

The particles may also have the property that the contact angle of water on the particle film is between 20 and 70 degrees. If the contact angle of water on the particle membrane is 20 degrees or more, it is preferable because it has appropriate hydrophilicity and the distribution of the active ingredient to intercellular lipids in the stratum corneum is improved. In addition, if the contact angle of water on the particle membrane is 70 degrees or less, it is preferable because it has appropriate hydrophobicity and is compatible with intercellular lipids in the stratum corneum. The contact angle may be preferably 25 degrees or more, more preferably 30 degrees or more, even more preferably 35 degrees or more, and particularly preferably 40 degrees or more. The contact angle may also be preferably 65 degrees or less, more preferably 60 degrees or less, even more preferably 55 degrees or less, and particularly preferably 50 degrees or less. When calculating the ratio, the internal angle is measured as the contact angle.
The contact angle of water on the particle film can be measured as follows. First, a film of particles (particle film) is obtained. For example, a solution containing particles is dropped onto a polystyrene substrate and air-dried at an appropriate temperature (eg, room temperature (27° C., etc.)) to obtain a particle film (particle film) that completely covers the polystyrene substrate. Next, after dropping a water droplet of 20 μL on the particle film thus obtained, an image is taken from the side. The contact angle value is measured from the image.

The particles may have the property that the ratio of the contact angle of water on the particle film to the contact angle of water on the polystyrene substrate is in the range of 0.2 to 0.9. If the said ratio is 0.2 or more, it can be said that it has moderate hydrophilicity with respect to the polystyrene substrate surface. In this case, it is considered that separation becomes difficult when blended into a formulation containing water. Therefore, it is preferable that the ratio is 0.2 or more. Moreover, if the said ratio is 0.9 or less, it can be said that it has moderate hydrophobicity. In this case, it is considered that separation becomes difficult when blended into formulations containing oil. Therefore, it is preferable that the ratio is 0.9 or less. The above ratio may be preferably 0.3 or more, more preferably 0.4 or more, even more preferably 0.5 or more. The ratio may also preferably be 0.8 or less, more preferably 0.7 or less, even more preferably 0.6 or less. When calculating the ratio, the internal angle is measured as the contact angle.
The contact angle of water on the particle film can be measured in the same manner as described above.
Measurement of the contact angle of water on a polystyrene substrate can be performed as follows. After dropping 20 μL of water droplets onto the polystyrene substrate, the contact angle value is measured by the same method as the measurement of the contact angle of water on the particle film.
Calculate the ratio of the contact angle of water on the particle film to the contact angle of water on the polystyrene substrate by dividing the contact angle value of water on the particle film by the contact angle value of water on the polystyrene substrate. be able to.

The particles may also have the property of having an absolute value of electrophoretic mobility of 2 μmcm/Vs or more. If the absolute value is 0.22 μmcm/Vs or more, the particles do not have a complete gel-like surface and the active ingredient can be retained inside the particles, which is preferable. Thus, the particles have well-bounded properties rather than a gel-like surface. The absolute value of the mobility may be preferably 2.5 μmcm/Vs or more, more preferably 3.0 μmcm/Vs or more, and even more preferably 3.5 μmcm/Vs or more. The absolute value of the mobility may also preferably be 6.0 μmcm/Vs or less. If the absolute value is 6.0 μm cm / Vs or less, the particles do not have hard and medium-impermeable surface properties (e.g., surface properties of polystyrene particles), but when in contact with biological tissue such as the skin surface It is preferred because it has surface properties that allow it to release the active ingredient with the vehicle at the appropriate time. The absolute value may be more preferably 5.5 μmcm/Vs or less, still more preferably 5.0 μmcm/Vs or less.
Electrophoretic mobility of particles can be measured by electrophoresis by analyzing the mobility of particles in a 1 mM NaCl aqueous solution using Zetasizer NanoS (manufactured by Malvern Instruments Ltd.).

The particles may also have negatively or positively charged surfaces. Preferably the particles have a negatively charged surface. The charge on the surface of the particles can be evaluated by measuring the mobility of the particles by electrophoresis as described above. More specifically, when the mobility of the particles shows a negative value as measured by electrophoresis as described above, the particles have a negatively charged surface, and when the mobility of the particles shows a positive value, Particles can be evaluated as having a positively charged surface.

The polymer particles may also be composite particles or non-composite particles. The term "composite particle" refers to a particle aggregate formed by the binding (eg, adsorption, adhesion) of two or more dissimilar particles. Such composite particles can be produced from two or more different particles by a predetermined method (eg, granulation method, particle composite method). On the other hand, non-composite particles are not such composite particles, and are not formed by bonding two or more different types of particles. Polymer particles can be suitably used in either the form of composite particles or non-composite particles. Moreover, since the desired properties can be sufficiently exhibited even in the form of non-composite particles, the form of non-composite particles can be preferably used.

The particles may also have a substantially uniform size. Here, "substantially uniform size" means that 50% or more (preferably 60% or more, more preferably 70% or more, still more preferably 80% or more, particularly preferably 90% or more) of the particles average It refers to being within a range of ±200 nm (preferably ±150 nm, more preferably ±100 nm) based on the particle size. The number of particles used for evaluating whether the particles have a substantially uniform size is 10, preferably 15, more preferably 20, even more preferably 30, and particularly preferably 50. is. Particles used for evaluation are particles randomly selected in the scanning electron microscope image, preferably a certain region in the scanning electron microscope image (one section covering the above number of particles (preferably are particles present in square compartments)). The particles may be substituted, in particular with at least one specific cellulose derivative, by another polymer (e.g. a cellulose derivative polymer other than the specific cellulose derivative, or by using a cellulose derivative as described above). Such high uniformity can be realized by using a polymer containing a divalent hydrocarbon group as a monomer unit in a predetermined production method.

Particles may also have a hard or soft surface. The particles may also have a spherical shape, an elliptical shape, a golf ball shape, a Janus particle shape, or the like, but preferably have a spherical shape. These properties of the particles can be confirmed by observing their appearance with a scanning electron microscope.

The particles also have high liquid stability. For example, the particles can maintain their particle state without agglomeration after being stored in refrigeration (eg, 4° C.) for 6 months or longer, 12 months or longer, or 18 months or longer.

Particles can be powdered. Examples of powdering methods include freeze drying, spray drying, fluid bed granulation, stirring granulation, supercritical granulation, and natural drying. The particles also have the property of being dispersible in a solvent (for example, the solvent described below, preferably an aqueous solution such as water) after pulverization.

The particles can be provided in liquid form, or in powdered form. If the particles are provided in liquid form, the particles are provided as a solution containing the particles.
Solutions include, for example, aqueous solutions and organic solvents.
Aqueous solutions include, for example, water (eg, distilled water, sterile distilled water, purified water, physiological saline), and buffer solutions. Examples of buffers include phosphate buffer, Tris-hydrochloric acid buffer, TE (Tris-EDTA) buffer, carbonate-bicarbonate buffer, borate buffer, tartrate buffer, hydrochloric acid-potassium chloride buffer, glycine-hydrochloric acid buffer, glycine-sodium hydroxide buffer, citrate buffer, citrate-phosphate buffer, acetate buffer.
The organic solvent is the same as that described later, and the preferred range is also the same.
Preferably the solution is an aqueous solution, more preferably water.

The particles also have a tissue permeation effect for the active ingredient. Examples of biological tissue through which the active ingredient can permeate include skin tissue (eg, stratum corneum), oral cavity, digestive tract, eye, and ear and nose cavity.

2. Method for Making Particles The present invention also provides a method for making particles. The method of the present invention comprises mixing (i) an organic solvent containing a cellulose derivative and (ii) an aqueous solution to precipitate particles. The active ingredient may be contained in either an organic solvent or an aqueous solution, or both, but is preferably contained in an aqueous solution.

In (i), the cellulose derivative contained in the organic solvent is not particularly limited as long as it is soluble in the organic solvent, but is preferably a hydrophobic polymer as described above. The amount of the cellulose derivative in the organic solvent is not particularly limited as long as the cellulose derivative can be dissolved in the organic solvent. wt), more preferably 0.2-10% (wt), even more preferably 0.3-7% (wt).

In (ii), the active ingredient and aqueous solution are the same as those described above. The amount of the active ingredient in the organic solvent or aqueous solution is not particularly limited as long as the active ingredient can be dissolved in the organic solvent or aqueous solution and the amount of the active ingredient for the intended use of the particles (e.g., medicine) can be achieved. For example, 0.01 to 50% (wt), preferably 0.02 to 40% (wt), more preferably 0.05 to 30% (wt), still more preferably 0.1 to 20% (wt) be. As the active ingredient, both water-soluble ingredients and hydrophobic ingredients as described above can be used.

When the organic solvent containing the cellulose derivative is mixed with an aqueous solution (preferably an aqueous solution containing an active ingredient), the aqueous solution (preferably an aqueous solution containing an active ingredient) can be phase-separated by the cellulose derivative dissolved in the organic solvent. is used. Examples of such organic solvents include ketone solvents (eg, acetone, methyl ethyl ketone, methyl isobutyl ketone, methyl butyl ketone), ether solvents (eg, diethyl ether, tetrahydrofuran, diisopropyl ether, dioxane), alcohol solvents (eg, methanol , ethanol, propanol, butanol), aprotic polar solvents (e.g., N-methyl-2-pyrrolidone (NMP), dimethylsulfoxide (DMSO), N,N-dimethylformamide (DMF), N,N-dimethylacetamide ( DMA)), carboxylic acid solvents (e.g. formic acid, acetic acid, propionic acid, butyric acid, lactic acid), ester solvents (e.g. ethyl acetate, butyl acetate, butyl propionate, butyl butyrate), halogenated hydrocarbon solvents (e.g. chloroform, methylene chloride, carbon tetrachloride, dichloroethane, trichloroethane, chlorobenzene), non-aromatic hydrocarbon solvents (e.g. pentane, hexane, heptane, octane, cyclohexane, cyclopentane), aromatic hydrocarbon solvents (e.g. benzene , toluene, xylene), and mixtures thereof.

Preferably, the organic solvent is an organic solvent miscible with an aqueous solution (preferably water) from the viewpoint of efficiently producing particles. Organic solvents miscible with the aqueous solution include, for example, ketone solvents, ether solvents, alcohol solvents, aprotic polar solvents, carboxylic acid solvents, and ester solvents. In view of the use of organic solvents that are miscible with aqueous solutions but not azeotropic with water, preferred organic solvents are acetone, alcohols (eg, methanol), or acetone-alcohol mixtures, which may be enriched with acetone.

The temperature during mixing is not particularly limited as long as the organic solvent and the aqueous solution are in a liquid state, and is, for example, 5 to 50°C, preferably 15 to 40°C. The mixing time is not particularly limited as long as the particles are formed, but is, for example, 5 to 60 minutes, preferably 15 to 30 minutes.

In one embodiment, the mixing can be performed, for example, by gradually adding (I) an organic solvent containing (i) a cellulose derivative to (ii) an aqueous solution. The active ingredient may be contained in either an organic solvent or an aqueous solution, or both, but is preferably contained in an aqueous solution. In this case, the amount of the organic solvent containing the cellulose derivative may be increased.

In another embodiment, the mixing can be performed, for example, by slowly adding the (II)(ii) aqueous solution to the (i) organic solvent containing the cellulose derivative. The active ingredient may be contained in either an organic solvent or an aqueous solution, or both, but is preferably contained in an aqueous solution. In this case, the amount of (ii) the aqueous solution containing the active ingredient to be added may be kept lower than the amount of (i) the organic solvent containing the cellulose derivative.

In a preferred embodiment, the method of the present invention comprises mixing (i′) an organic solvent containing the first polymer and (ii′) an aqueous solution containing both the active ingredient and the second polymer to precipitate the particles. include. In the method for producing particles, by using the first polymer in the organic solvent and the second polymer in the aqueous solution together, the produced particles can have the properties of both water-soluble gel and hard properties. There is

Definitions, examples and preferred examples of the first polymer, the organic solvent, and the amount of the first polymer in the organic solvent in (i′) are the cellulose derivative, the organic solvent, and the cellulose in the organic solvent mentioned in (i). Similar to the amount of derivatives.

Definitions, examples and preferred examples of the active ingredient, the aqueous solution, and the amount of the active ingredient in the aqueous solution in (ii') are the same as those described in (ii).

In (ii'), the second polymer contained in the aqueous solution is not particularly limited as long as it is soluble in the aqueous solution, but is preferably a hydrophilic polymer as described above. The amount of the polymer in the aqueous solution is not particularly limited as long as the polymer can be dissolved in the aqueous solution. Preferably from 0.005 to 7% (wt), even more preferably from 0.01 to 5% (wt).

In certain preferred embodiments, the mixing comprises, for example, (I′) gradually adding an organic solvent containing (i′) the first polymer to (ii′) an aqueous solution containing both the active ingredient and the second polymer. It can be done by In this case, the amount of the organic solvent containing the cellulose derivative may be increased.

In another embodiment, the mixing is, for example, (II') (ii') slowly adding an aqueous solution containing both the active ingredient and the second polymer to (i') an organic solvent containing the first polymer. can be done by In this case, the amount of (ii') the aqueous solution containing both the active ingredient and the second polymer to be added may be kept lower than the amount of (i') the organic solvent containing the first polymer.

The addition can preferably be effected dropwise. During the addition, the solution can be placed under stirring conditions. Stirring conditions can be appropriately set according to the amount of the solution. For example, it is 200-800 rpm (preferably 400 rpm) on a scale with a final liquid volume of about 45 mL, and 80-230 rpm on a scale with a final liquid volume of about 1 L.

3. Compositions The amount of active ingredient in an oral solid composition is no more than 10% by weight. The amount of active ingredient in the oral solid composition is preferably 9% by weight or less, more preferably 8% by weight or less, even more preferably 7% by weight or less, and particularly preferably 5% by weight or less, 4% by weight or less, and 3% by weight. % or less, 2 wt % or less, or 1 wt % or less.

The oral solid composition may contain, as particles, only polymer particles of the same type, or may contain polymer particles of different types. The term "homogeneous polymer particles" refers to polymer particles that are similar in size and composition. Polymer particles that are produced under the same conditions (eg, similar types and amounts of components, and similar processing modes) can be considered homogenous polymer particles. On the other hand, the term "heterogeneous polymer particles" refers to polymer particles that differ in particle size and/or composition. Polymer particles that are produced under different conditions (eg, different in either the type and amount of ingredients and in the processing conditions) can be considered heterogeneous polymer particles. Even if the oral solid composition contains only polymer particles of the same type as the polymer particles, the desired properties can be sufficiently exhibited. Therefore, from the viewpoint of reducing the burden of preparing / obtaining particles, etc. It may contain only homogenous polymer particles. Thus, oral solid compositions may preferably be free of polymer particles with an average particle size greater than 1 μm.

Oral solid compositions can be applied to animals, preferably mammals such as humans. Although the dosage varies depending on the type, age, weight, disease state, administration method, etc. of the target animal, it can be appropriately set according to the type of active ingredient contained in the particles.

The solid oral composition may further contain one or more active ingredients as described above, apart from the active ingredients contained in the particles. Preferably, the active ingredient further included in the oral solid composition may be the same or different than the active ingredient that may be included in the particles included in the oral solid composition, but is preferably different.

The oral solid composition may also contain suitable pharmaceutically acceptable carriers such as excipients, stabilizers, preservatives, antioxidants, colorants, lubricants, if desired, for the particles. , as well as food base materials and the like may be blended.

Examples of excipients that can be used include sugars such as lactose, glucose and D-mannitol, organic excipients such as celluloses such as crystalline cellulose, and inorganic excipients such as calcium carbonate and kaolin. can. Components such as polyethylene glycol, sodium dextran sulfate, and other amino acids can be used as stabilizers. Examples of preservatives that can be used include paraoxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, and sorbic acid. Components such as sulfites and ascorbic acid can be used as antioxidants. Coloring agents commonly used in the fields of medicine and cosmetics can be used as the coloring agent. Components such as magnesium stearate can be used as lubricants. In addition, when the oral solid composition is a drug or food such as candy, gum, chocolate, gummy, etc., the base material may be sucrose, starch syrup, sucrose, gelatin, ion exchange resin, xylitol, acesulfame potassium, aspartame, Sodium bicarbonate, sodium carbonate, magnesium oxide, talc, peppermint oil, l-menthol, gum arabic powder, titanium oxide, carnauba wax, calcium carbonate, dibutyl hydroxytoluene, fragrance, pigment, vegetable resin, thermoplastic resin and elastomer, cacao Fats, cocoa powder, sucrose fatty acid esters, and the like can be used.

A solid oral composition may be used as a liquid at the time of use, as long as it takes a solid form before use (eg, at the time of manufacture). Thus, oral solid compositions include not only compositions that are solid prior to and at the time of use, but also compositions that are ingested as liquid compositions at the time of use but are solid prior to use (e.g., dry syrups). Also included are those that arrive in solid form at the patient's hand and are liquid when ingested). Oral solid compositions can be used, for example, as pharmaceuticals (eg, therapeutic agents, prophylactic agents) and foods (eg, nutritional supplements, confectionery). Pharmaceuticals include, for example, tablets (eg, chewable tablets, sublingual tablets), capsules, granules, powders, fine granules, dry syrups, cashews, pills, drops, and troches. These medicaments may be sustained release. Pharmaceuticals or foods include gums, chocolates, and gummies. Preferably, an oral solid composition can be used as a medicament.

4. Set The set of the present invention comprises 10 or more oral solid compositions as described above. The number of oral solid compositions as unit dosage forms included in the set of the present invention may preferably be 15 or more, more preferably 20 or more, even more preferably 30 or more, particularly preferably 50 or more. . The number of oral solid compositions as unit dosage forms included in the set of the invention is also preferably no more than 1000, more preferably no more than 500, even more preferably no more than 200, especially preferably no more than 100. good. Even when the set of the present invention contains such a number of oral solid compositions, the content uniformity judgment value of the active ingredient shows a value of less than 10%. The content uniformity determination value of the active ingredient is preferably less than 9%, more preferably less than 8%, even more preferably less than 7%, particularly preferably less than 5%, less than 4%, less than 3%, less than 2% or It may be less than 1%.
The content uniformity of the active ingredient can be evaluated according to the 17th revision of the Japanese Pharmacopoeia, general test, test method for uniformity of formulation, test method for uniformity of formulation, content uniformity test (see Examples for details). More specifically, 30 or more samples are taken and tested according to the method shown below (see also Examples). Correction factors may be required when different measurement methods are used for assay and content uniformity. For 10 samples, the active ingredient content in each preparation is measured by an appropriate method, and the judgment value is calculated. Unless otherwise specified in the above Pharmacopoeia, the following criteria shall apply. Calculate the judgment value for the first 10 samples, and if the value does not exceed L1%, it is acceptable.

If the judgment value exceeds L1%, the remaining 20 samples are similarly tested and the judgment value is calculated. The judgment value of 30 samples combined from the two tests did not exceed L1%, and the content of each formulation was shown in the "calculation of judgment value" section of the content uniformity test or mass deviation test ( 1-L2 x 0.01) M or more, and if there is no item exceeding (1 + L2 x 0.01) M, it is qualified. L1 is 15.0 and L2 is 25.0, unless otherwise specified in the pharmacopoeia. When the number of oral solid compositions contained in one set of the present invention is 10 or more and less than 30, 30 samples (oral solid compositions) cannot be taken from one set. In this case, 10 instead of 30 samples can be taken from the set of the present invention for content uniformity testing. Alternatively, 30 or more samples (oral solid compositions) may be taken from one set and a set of a plurality of sets manufactured at the same time, and a content uniformity test may be performed. When the number of oral solid compositions contained in one set of the present invention is 30 or more, a sample (oral solid composition Item) 30 or more can be taken and a content uniformity test can be performed. Alternatively, even in this case, 10 instead of 30 samples from the set of the present invention may be taken for content uniformity testing. Preferably, when the number of oral solid compositions contained in one set of the present invention is 30 or more, 30 or more samples (oral solid compositions) are taken from only the one set, and a content uniformity test is performed. may From the viewpoint of performing the content uniformity test as described above only from the samples (oral solid compositions) included in one set of the present invention, the number of oral solid compositions as unit dosage forms included in the set of the present invention is 30. It is preferable that the number is one or more.

The oral solid compositions as unit dosage forms included in the set of the present invention are 10 or more oral solid compositions in separable form (e.g. tablets, capsules, dry syrups, cashews, pills, lozenges, lozenges). , gums, chocolates, and gummies) may be contained in a single package (e.g., bag or container), or 10 or more oral solid compositions (e.g., tablets, capsules, granules). , powders, fine granules, dry syrups, cashews, pills, drops, lozenges) may be individually packaged (eg, PTP packaging, SP packaging).

EXAMPLES Next, the present invention will be described in more detail with reference to examples, but the present invention is not limited to the following examples.

<Production Example 1> Preparation of tranexamic acid-encapsulating polymer microparticles First, the following three types of solutions were prepared.
(1) Polymer liquid 1
Polymer liquid 1 was prepared by dissolving 8 g of ethyl cellulose (STD7FP manufactured by Dow Chemical Co., weight average molecular weight: 55,025) in 600 mL of acetone.
(2) Polymer liquid 2
Polymer liquid 2 was prepared by dissolving 2 g of hydroxypropyl cellulose (manufactured by Nippon Soda Co., Ltd., SL; weight average molecular weight: 100,000) in 328 mL of water.
(3) Liquid Containing Active Ingredient As the active ingredient, 10.0 g of tranexamic acid (manufactured by Maruzen Pharmaceutical Co., Ltd.) was used.

Then, the active ingredient was dissolved in the polymer liquid 2 stirred at 40° C. and 250 rpm to obtain a homogeneous liquid. Polymer liquid 1 was gradually added dropwise to this uniform liquid. During the addition of polymer liquid 1, the homogeneous liquid was stirred at 250 rpm. The dropwise addition of the polymer liquid 1 made the liquid cloudy. As a result, particles containing tranexamic acid, hydroxypropyl cellulose, and ethyl cellulose spontaneously and rapidly precipitated by dropping the polymer liquid 1, and a suspension containing such particles was obtained. This suspension was aspirated under reduced pressure while stirring to remove acetone, thereby obtaining a particle liquid dispersed in water.

(4) Drying method The obtained particle liquid was dried by a spray dryer (B-290, manufactured by Buchi Co.) until the water content was completely eliminated instantaneously.

<Production Example 2> Preparation of cimetidine-encapsulating polymer microparticles Production Example 1 was the same as Production Example 1, except that 10.0 g of tranexamic acid in the active ingredient-containing liquid of Production Example 1 was changed to 2.0 g of cimetidine (manufactured by Tokyo Chemical Industry Co., Ltd.). Prepared similarly.

<Production Example 3> Preparation of minoxidil-encapsulating polymer fine particles 1 (1) Polymer liquid 1
Polymer liquid 1 was prepared by dissolving 12 g of hypromellose acetate succinate (manufactured by Shin-Etsu Chemical Co., Ltd., AS-MG, weight average molecular weight: 17,933) in 400 mL of methanol.
(2) Polymer liquid 2
Polymer liquid 2 was prepared by dissolving 3 g of hydroxypropyl cellulose (SL, manufactured by Nippon Soda Co., Ltd., weight average molecular weight: 100,000) in 300 mL of water.
(3) Active Ingredient-Containing Liquid In polymer liquid 1, 15.0 g of minoxidil (manufactured by OXCHEM) was dissolved as an active ingredient.

Then, the polymer liquid 1 containing minoxidil was dropped into the polymer liquid 2 being stirred at 40° C. and 200 rpm to obtain a uniform liquid. While continuing to stir this homogeneous liquid, methanol was distilled off under reduced pressure using a vacuum pump (manufactured by ULVAC KIKO, DTC-66, 60 L/min). A white turbid liquid with particles was obtained. As a result, particles containing minoxidil, hydroxypropylcellulose, and hypromellose acetate succinate precipitated spontaneously and quickly, and a suspension containing such particles was obtained.

(4) Drying Method The obtained particle liquid was dried with a freeze dryer (FM25EL-85, manufactured by SP Scientific) at −80° C. and 20 mPa until the water content was completely removed.

<Production Example 4> Preparation of minoxidil-encapsulating polymer fine particles 2 (1) Polymer liquid 1
Polymer liquid 1 was prepared by dissolving 12.0 g of ethyl cellulose (STD4, manufactured by Dow Chemical Co., weight average molecular weight: 44,046) in 400 mL of amethanol.
(2) Polymer liquid 2
Polymer liquid 2 was prepared by dissolving 3.0 g of hydroxypropyl cellulose (manufactured by Nippon Soda Co., Ltd., SL; weight average molecular weight: 100,000) in 300 mL of water.
(3) Active Ingredient-Containing Liquid In polymer liquid 1, 15.0 g of minoxidil (manufactured by OXCHEM) was dissolved as an active ingredient.

Then, the polymer liquid 1 in which the active ingredient was dissolved was gradually added dropwise to the polymer liquid 2 being stirred at 40° C. and 250 rpm. During the addition of polymer liquid 1, the liquid was stirred at 250 rpm. The dropwise addition of the polymer liquid 1 made the liquid cloudy. As a result, particles containing minoxidil, hydroxypropyl cellulose, and ethyl cellulose spontaneously and rapidly precipitated by dropping the polymer liquid 1, and a suspension containing such particles was obtained. This suspension was aspirated under reduced pressure while stirring to remove methanol, thereby obtaining a particle liquid dispersed in water.

(4) Drying Method The obtained particle liquid was dried with a freeze dryer (FM25EL-85, manufactured by SP Scientific) at −80° C. and 20 mPa until the water content was completely removed.

<Production Example 5> Preparation of Diclofenac Sodium-encapsulating Polymer Microparticles 10.0 g of tranexamic acid in the active ingredient-containing liquid of Production Example 1 was replaced with 2.0 g of diclofenac sodium (manufactured by Sigma-Aldrich). Chemical Co., STD7FP, weight average molecular weight: 55,025) was changed to ethyl cellulose (Dow Chemical Co., STD10, weight average molecular weight: 77,180) 8 g was prepared in the same manner as in Production Example 1.

<Method for preparing compositions of Examples 1 to 5 and Comparative Examples 1 to 5>
The raw materials listed in Table 1 were weighed so that the total amount was 200 g, mixed uniformly, and then a single tableting machine (manufactured by Fuji Yakuhin Kikai, FY-TQMB-30) so that each tablet was 200 mg. It was tableted to obtain a test sample.

<Content uniformity evaluation>
・Evaluation method Evaluation was performed according to the Japanese Pharmacopoeia 17th revision general test, formulation uniformity test method, content uniformity test method, and judgment values were used. (Evaluated with 10 tablets)
Formula |M−X|+ks
(X: average value of 10 tablets, M: M = X when 98.5% ≤ X ≤ 101.5%, M = 98.5% when X < 98.5%,
When X > 101.5%, M = 101.5%, k: 2.4 (constant, for 10 tablets), s: standard deviation of 10 tablets)

・Judgment criteria A: judgment value is 0% or more and less than 5%, B: judgment value is 5% or more and less than 10%, C: judgment value is 10% or more

[Reference Example 1] Preparation of Particle 1 First, the following three kinds of solutions were prepared.
(1) Polymer liquid 1
Polymer liquid 1 was prepared by dissolving 0.4 g of ethyl cellulose (STD7FP manufactured by Dow Chemical Co., weight average molecular weight: 55,025) in 30 mL of acetone.
(2) Polymer liquid 2
Polymer liquid 2 was prepared by dissolving 0.1 g of hydroxypropyl cellulose (manufactured by Nippon Soda Co., Ltd., SL; weight average molecular weight: 100,000) in 15 mL of water.
(3) Active ingredient-containing liquid An active ingredient-containing liquid was prepared by dissolving 0.1 g of tranexamic acid (manufactured by Maruzen Pharmaceutical Co., Ltd.) in 1.5 mL of water.

Next, a suspension containing particles containing tranexamic acid, hydroxypropyl cellulose, and ethyl cellulose was obtained by the same method as in Examples. This suspension was aspirated under reduced pressure while stirring to remove acetone, thereby obtaining a particle liquid dispersed in water. After that, the particle size distribution was evaluated with a laser diffraction particle size analyzer (ZetasizerNanoS, manufactured by Malvern Instruments Ltd.) (see Table 2 below).

Also, the obtained particles were photographed with a scanning electron microscope. A scanning electron micrograph is shown in FIG.

[Reference Example 2] Preparation of Particles 2 The amount of tranexamic acid in Reference Example 1 was changed to 2.0 g, and tranexamic acid was added directly to polymer liquid 2 without preparing a solution in which tranexamic acid was dissolved in the active ingredient-containing liquid. A particle liquid was prepared in the same manner as in Reference Example 1 except that polymer liquid 1 and polymer liquid 2 were used, and the particle size distribution was measured (see Table 2 below).

[Reference Example 3] Preparation of Particle 3 First, the following three kinds of solutions were prepared.
(1) Polymer liquid 1
Polymer liquid 1 was prepared by dissolving 8 g of ethyl cellulose (STD7FP manufactured by Dow Chemical Co., weight average molecular weight: 55,025) in 600 mL of acetone.
(2) Polymer liquid 2
Polymer liquid 2 was prepared by dissolving 2 g of hydroxypropyl cellulose (manufactured by Nippon Soda Co., Ltd., SL; weight average molecular weight: 100,000) in 300 mL of water.
(3) Active ingredient-containing liquid An active ingredient-containing liquid was prepared by dissolving 2 g of tranexamic acid (manufactured by Maruzen Pharmaceutical Co., Ltd.) in 30 mL of water.

Next, a suspension containing particles containing tranexamic acid, hydroxypropyl cellulose, and ethyl cellulose was obtained by the same method as in Examples. This suspension was aspirated under reduced pressure while stirring to remove acetone, thereby obtaining a particle liquid dispersed in water. After that, the particle size distribution was evaluated with a laser diffraction particle size analyzer (ZetasizerNanoS, manufactured by Malvern Instruments Ltd.) (see Table 2 below).

[Reference Example 4] Preparation of Particle 4 The ethyl cellulose of Reference Example 1 was added to hypromellose acetate succinate (Shin-Etsu Chemical Co., Ltd., AS-MG, weight average molecular weight: 18,000), and the acetone of polymer liquid 1 was added to methanol. A particle liquid was prepared in the same manner as in Reference Example 1 except for changing to , and the particle size distribution was measured (see Table 2 below).

[Reference Example 5] Preparation of Particle 5 The same procedure as in Reference Example 1 was performed except that the ethyl cellulose in Reference Example 1 was changed to hypromellose phthalate (Shin-Etsu Chemical Co., Ltd., HP-55, weight average molecular weight: 84,000). A particle liquid was similarly prepared and the particle size distribution was measured (see Table 2 below). The hypromellose phthalate ester (HP-55) used has a pH solubility of ≧5.5 and a display viscosity of 40 mPa s [10% solution viscosity of a methanol/dichloromethane solution (1:1) at 20° C. (Japan Pharmacopoeia)] properties.

[Reference Example 6] Preparation of Particles 6 A particle liquid was prepared in the same manner as in Reference Example 1, except that ethyl cellulose in Reference Example 1 was changed to methacrylic acid copolymer S (S-100, manufactured by Evonik, weight average molecular weight: 125,000). were prepared and the particle size distribution was measured (see Table 2 below).

[Reference Comparative Example 1] Preparation of Comparative Particles 1 Except that the (3) active ingredient-containing liquid (0.1 g of tranexamic acid dissolved in 1.5 mL of water) in Reference Example 1 was changed to 1.5 mL of water. A particle liquid was prepared in the same manner as in Reference Example 1, and the particle size distribution was measured (see Table 2 below).

(Summary of results of Reference Examples 1 to 6 and Reference Comparative Example 1)
Table 2 shows the particle size distribution results measured in Reference Examples 1 to 6 and Reference Comparative Example 1.

[Reference Example 7] Preparation of Particle 7 An experiment was conducted in the same manner as in Reference Example 1, except that 0.1 g of tranexamic acid in Reference Example 1 was changed to 0.01 g of Food Red No. 3 (manufactured by Hodogaya Chemical Industry Co., Ltd.). . As a result, formation of particles was confirmed.

[Reference Examples 8-11] Preparation of Particles 8-11 The experiment was conducted in the same manner as in Reference Example 3, except that any one substance selected from the group consisting of Kasei Kogyo Co., Ltd.) was used. As a result, the formation of particles was confirmed when any substance was used.

[Reference Examples 12 and 13] Preparation of Particles 12 and 13 In Reference Example 3, tranexamic acid was changed to either L-valine (manufactured by Ajinomoto) or sodium L-glutamate (manufactured by Ajinomoto), and acetone was changed to methanol. An experiment was conducted in the same manner as in Reference Example 3 except for the above. As a result, the formation of particles was confirmed when any substance was used.

[Reference Example 14] Preparation of Particle 14 Same as Reference Example 3, except that 2 g of tranexamic acid in Reference Example 3 was changed to 4 g of pyrrolidone carboxylic acid (PCA) sodium salt 50% (wt) aqueous solution (NL-50, manufactured by Ajinomoto). and conducted an experiment. As a result, formation of particles was confirmed.

[Reference Example 15] Examination of grade of hydroxypropyl cellulose An experiment was conducted in the same manner as in Reference Example 7, except that the grade of hydroxypropyl cellulose (HPC) in Reference Example 7 was changed as shown in Table 3 below. As a result, the formation of particles was confirmed (Table 3).

[Reference Example 16] Examination of Grade of Ethyl Cellulose An experiment was conducted in the same manner as in Reference Example 7, except that the grade of ethyl cellulose (EC) in Reference Example 7 was changed as shown in Table 4 below. As a result, the formation of particles was confirmed (Table 4).

[Reference Example 17] Examination of grade of hypromellose acetate succinate The grade of hypromellose acetate succinate (manufactured by Shin-Etsu Chemical Co., Ltd., AS-MG) of Reference Example 4 was changed as shown in Table 5 below. An experiment was conducted in the same manner as in Reference Example 4 except for the above. As a result, formation of particles was confirmed.

[Reference Example 18] Examination of grade of methacrylic acid copolymer Methacrylic acid copolymer S (manufactured by Evonik, S-100) of Reference Example 6 was converted to methacrylic acid copolymer L (manufactured by Evonik, L100. Weight average molecular weight: 125,000). An experiment was conducted in the same manner as in Reference Example 6, except for the change. As a result, formation of particles with an average particle diameter of 747 nm was confirmed in methacrylic acid copolymer L (L100).

[Reference Example 19] Examination of preparation of particles using one type of polymer (1) Use of organic solvent containing no hydrophobic polymer ) The experiment was conducted in the same manner as in Reference Example 1, except that the amount was 0.01 g and ethyl cellulose was not used. As a result, no particle formation was confirmed.
From the above, it was confirmed that particles were not formed when an organic solvent containing no hydrophobic polymer (non-polymer liquid instead of polymer liquid 1) and an aqueous solution containing a hydrophilic polymer (polymer liquid 2) were used. rice field.
(2) Use of an aqueous solution containing no hydrophilic polymer 0.1 g of tranexamic acid in Reference Example 1 was changed to 0.01 g of Food Red No. 3 (manufactured by Hodogaya Chemical Industry Co., Ltd.), and hydroxypropyl cellulose was not used. An experiment was carried out in the same manner as in Example 1. As a result, the formation of particles was confirmed (result of dynamic light scattering measurement: average particle size 217 nm).
From the above, it was confirmed that particles were formed when an organic solvent containing a hydrophobic polymer (polymer liquid 1) and an aqueous solution containing no hydrophilic polymer (non-polymer liquid instead of polymer liquid 2) were used. was done.

[Reference Example 20] Preparation of particles by changing the dropping mode 0.1 g of tranexamic acid of Reference Example 1 is mixed with 0.01 g of food red No. 3 (manufactured by Hodogaya Chemical Industry), polymer liquid 2 and a liquid containing an active ingredient. An experiment was conducted in the same manner as in the example, except that the was dropped into the polymer liquid 1. In this experimental condition, a small amount of aqueous solution is added to a large amount of organic solvent. As a result, formation of particles was confirmed.

[Reference Examples 21, 22, 23] Preparation of Particles 15, 16, 17 Instead of tranexamic acid in Reference Example 1, methyl 4-hydroxybenzoate (methylparaben, manufactured by Junsei Chemical), minoxidil (manufactured by Tokyo Kasei), or dihydroxy An experiment was conducted in the same manner as in Reference Example 1, except that any active ingredient of capsiate (manufactured by Ajinomoto Co., Ltd.) was dissolved in polymer liquid 1 without preparing an active ingredient-containing liquid. As a result, the formation of particles was confirmed when any substance was used. It was also confirmed that particles containing an active ingredient can be obtained by dissolving the active ingredient in an organic solvent (polymer liquid 1) instead of an aqueous solution.

[Reference Test Example 1] Epidermal model permeability evaluation 1
First, the particle liquid prepared in Reference Example 3 was centrifuged at a centrifugal acceleration of 21500×g for 15 minutes in a centrifuge (CF-15RN, manufactured by Hitachi Koki Co., Ltd.), and the same amount of water as the removed supernatant was added. A washing operation for re-dispersing the particles was performed to obtain a purified particle liquid. A part of this purified particle liquid is centrifuged again to separate the washing liquid and the particles, and the liquid obtained by extracting tranexamic acid from the particle part with a high-speed chromatographic mobile phase containing methanol etc. is analyzed, and the tranexamic acid in the particles is analyzed. pre-determined amount. As a result, the amount of tranexamic acid relative to the weight of the particles was 6% (wt).

Next, the permeability was evaluated using a human three-dimensional cultured epidermis model in which human normal epidermal cells were overlaid and cultured. The donor side of a jacketed stationary Franz cell (manufactured by Permegia) in which a three-dimensional cultured epidermis model (manufactured by Japan Tissue Engineering Co., Ltd., Epi Model 12) is set, so that 0.2 mg of tranexamic acid is included. After 24 hours from the placement of the purified particle liquid, the concentration of tranexamic acid on the receiver side was measured with a high-speed chromatograph (H-CLASS, manufactured by Nippon Waters Co., Ltd.) to determine the amount of permeation (see Table 6 below).

[Reference Test Example 2] Epidermal model permeability evaluation 2
The epidermal model permeability was evaluated in the same manner as in Reference Test Example 1, except that the particle liquid used in the centrifugal purification of Reference Test Example 1 was changed to the particle liquid prepared in Reference Example 4 (see Table 6 below).

[Reference Comparative Test Example 1] Epidermal model permeability evaluation 3
Epidermal model permeability was evaluated in the same manner as in Reference Test Example 1, except that the purified particle liquid in Reference Test Example 1 was changed to a 4 mg/mL tranexamic acid aqueous solution (see Table 6 below).

[Reference Comparative Test Example 2] Epidermal model permeability evaluation 4
Epidermal model permeability in the same manner as in Reference Test Example 1 except that the particle liquid used for centrifugal purification in Reference Test Example 1 was changed to the particle liquid prepared in Reference Comparative Example 1, and 0.2 mg of tranexamic acid was added later. was evaluated (see Table 6 below).

(Summary of results of Reference Test Examples 1 and 2 and Reference Comparative Test Examples 1 and 2)
Table 6 shows the results of the amount of permeation after 24 hours in Reference Test Examples 1 and 2 and Reference Comparative Test Examples 1 and 2.

[Reference Test Example 3] Confirmation of properties of particles The particle liquid obtained in Reference Example 3 was air-dried and observed with a scanning electron microscope. The surface of the particles obtained in Reference Example 3 was found to be hard, It was also confirmed that the particles were spherical (Fig. 2).

In addition, 50 μL of the particle liquid obtained in Reference Example 3 was dropped onto a polystyrene substrate and allowed to air dry at room temperature (25° C.) for 24 hours. The image was taken from the side by dripping water droplets. When the contact angle was measured from the image using image processing software image J, the contact angle (inner angle) of water on the particle film was 43.9 degrees. On the other hand, when 20 μL of water droplets were dropped on the polystyrene substrate and the contact angle was similarly measured, the contact angle (inner angle) of water on the polystyrene substrate was 78.4 degrees. Since the contact angle of water on the particle film showed a smaller value than the contact angle of water on the polystyrene substrate, the surface of the particles obtained in Reference Example 3 was found to have hydrophilic properties. confirmed.

Furthermore, the particles prepared in Reference Example 3 were subjected to measurement of electrophoretic mobility in a 1 mM NaCl aqueous solution (Zetasizer NanoS, manufactured by Malvern Instruments Ltd.). As a result, the mobility by electrophoresis was −4.1±0.12 μm cm/Vs. The large absolute value from 0 μmcm/Vs confirmed that the particles were not hydrophilic gel particles.

From the above results, it was confirmed that the particles prepared in Reference Example 3 had both a hard surface like polystyrene particles and a soft gel-like surface like polyacrylamide or polyN,N isopropylacrylamide particles. was done. It was also confirmed that the particles, once formed, do not instantly dissolve and break even when dispersed in oil, an organic solvent, or water.

[Reference Test Example 4] Evaluation of storability and cohesiveness of particles (1) Evaluation of storability under non-freezing conditions The particle state was maintained without agglomeration even after years of storage. Therefore, it was confirmed that the particles are excellent in storage stability.
(2) Evaluation of Particle Dispersibility after Freeze-Drying The particle liquid prepared in Reference Example 3 was agitated and sucked under reduced pressure to reduce water to 1/10, followed by freeze-drying to obtain a powder. It was confirmed that when this powder was again dispersed in water so that the solid content concentration was 3% (wt), the original particle liquid was obtained.
(3) Evaluation of particle dispersibility after spray drying The particle liquid prepared in Reference Example 3 is agitated and vacuum-sucked to reduce the amount of water to 1/10, and then spray-dried (B-290 manufactured by Nippon Buchi Co., Ltd.) to obtain powder. Obtained. It was confirmed that when this powder was again dispersed in water so that the solid content concentration was 3% (wt), the original particle liquid was obtained.

[Reference Test Example 5] Epidermal model permeability evaluation 5
Particles 15, 16, and 17 obtained as described above were evaluated for the skin model permeability in the same manner as in Reference Test Examples 1 and 2 and Reference Comparative Test Examples 1 and 2. The results confirmed that these particles containing the active ingredient were more permeable in the epidermal model than a simple solution of the active ingredient.

[Reference Comparative Examples 2 to 19] Preparation of Comparative Particles 2 to 19 0.4 g of ethyl cellulose in polymer liquid 1 of Reference Example 7 was mixed with polylactic-co-glycolic acid block copolymer (PLGA5015, manufactured by Wako Pure Chemical Industries), cetanol (NAA- 44, manufactured by NOF), white petrolatum (manufactured by Ogi Pharmaceutical), castor wax (manufactured by NOF), stearyl alcohol (NAA-45, manufactured by NOF), stearic acid (NAA-180P-1, manufactured by NOF), propylene Glycol caprylate (SEFSOL-218, manufactured by Nikko Chemicals), propylene glycol dicaprylate (SEFSOL-228, manufactured by Nikko Chemicals), lipophilic glyceryl monooleate (MGO, manufactured by Nikko Chemicals), lipophilic monostearate Glycerin (MGS-AMV, manufactured by Nikko Chemicals), lipophilic glycerin monostearate (MGS-BMV, manufactured by Nikko Chemicals), polyethylene glycol distearate (CDS-6000P, manufactured by Nikko Chemicals), sucrose fatty acid ester (L-595) , Mitsubishi Kagaku Foods), sucrose fatty acid ester (S-570, Mitsubishi Kagaku Foods), sucrose fatty acid ester (S-770, Mitsubishi Kagaku Foods), polyoxyl 40 stearate (NIKKOL MYS-40MV, Nikko Chemicals ), cetomacrogol 1000 (NIKKOL BC-23, manufactured by Nikko Chemicals), polyoxyethylene (160) polyoxypropylene (30) glycol (Pronon #188, manufactured by NOF), povidone (K-30, manufactured by BASF), Copolyvidone (VA64, manufactured by BASF), saturated polyglycolized glycerides (Gelucire 50/13, manufactured by Gattefosse), PEG20000 (manufactured by Wako Pure Chemical Industries), polyvinyl alcohol (JMP-10L, manufactured by Nippon Vinyl Poval), polyvinyl alcohol (LL) -810, made by Japan Vinyl Acetate and Poval), polyvinyl alcohol (LL-920, made by Japan Vinyl Acetate and Poval), polyvinyl alcohol (LL-940, made by Japan Acetate and Poval) to 0.1 g, acetone 30 mL to 15 mL , 0.1 g of hydroxypropyl cellulose of polymer liquid 2 was changed to 0.6 g of polyvinyl alcohol (EG-05, manufactured by Nippon Synthetic Chemical Industry), 15 mL of water was changed to 30 mL, and 0.13 g of polysorbate 80 was added. Experiments were carried out analogously to Example 7 (Tables 7, 8). As a result, the formation of particles was confirmed when any substance was used. However, the evaluation of permeability using a three-dimensional cultured epidermis model showed no permeability within 24 hours.

[Reference Comparative Examples 20 to 27] Preparation of Comparative Particles 20 to 27 Experiments were conducted in the same manner as in Reference Comparative Example 2, except that water was used instead of acetone in the polymer liquid 1 of Reference Comparative Example 2 ( Table 9). As a result, the formation of particles was confirmed when any substance was used. However, the evaluation of permeability using a three-dimensional cultured epidermis model showed no permeability within 24 hours.

[Reference Comparative Examples 28 and 29] Preparation of Comparative Particles 28 and 29 Povidone (K-90, manufactured by BASF) and PEG6000 (manufactured by Wako Pure Chemical Industries) were used instead of polyvinyl alcohol in the polymer liquid 2 of Reference Comparative Example 2. An experiment was conducted in the same manner as in Reference Comparative Example 2, except that one of the components was used (Table 9). As a result, the formation of particles was confirmed when any substance was used. However, the evaluation of permeability using a three-dimensional cultured epidermis model showed no permeability within 24 hours.

Oral solid compositions are useful for products such as pharmaceuticals and foods.

Claims (18)

10 or more oral solid compositions in a unit dosage form;
The oral solid composition comprises the following components (i)-(iii) and comprises particles having properties (a)-( c ):
(i) one or more polymers selected from the group consisting of hydroxyalkylcellulose, carboxyalkylcellulose, cationized cellulose, and ester derivatives thereof, and salts thereof;
(ii) (ii-1) alkyl cellulose, hydroxyalkyl alkyl cellulose, hydrophobized cellulose, ester derivatives thereof, and salts thereof, and (ii-2) alkylene-based polymers and copolymers thereof, and salts thereof one or more polymers selected from the group; and (iii) an active ingredient;
(a) the active ingredient is contained inside the particle;
(b) a volume distribution average particle size of 1 to 900 nm;
(c) the particles have the property that the contact angle of water on the particle film is between 20 and 70 degrees;
A set of oral solid compositions, wherein the amount of active ingredient in said oral solid composition is 10% by weight or less and has a content uniformity criterion of less than 10%. The set of claim 1, wherein the particles have the property that the ratio of the contact angle of water on the particle film to the contact angle of water on the polystyrene substrate is in the range of 0.2 to 0.9. 3. The set according to claim 1, wherein said particles have the property that the absolute value of electrophoretic mobility is 2 μm cm/Vs or more. A set according to any one of claims 1 to 3, wherein the surface of the particles is negatively charged. A set according to any preceding claim, wherein the particles are substantially free of plasticizer. The set according to any one of claims 1 to 5, wherein said polymer (i) is one or more polymers selected from the group consisting of hydroxyalkylcellulose, carboxyalkylcellulose, and salts thereof. hydroxyalkyl cellulose is hydroxyethyl cellulose or hydroxypropyl cellulose,
7. The set of claim 6, wherein the carboxyalkylcellulose is carboxymethylcellulose. 8. Any one of claims 1 to 7, wherein the polymer (ii) is one or more polymers selected from the group consisting of alkylcellulose, hydroxyalkylalkylcellulose, ester derivatives of hydroxyalkylalkylcellulose, and salts thereof. or a set described in one item. the alkyl cellulose is methyl cellulose or ethyl cellulose,
hydroxyalkylalkylcellulose is hydroxypropylmethylcellulose,
9. The set according to claim 8, wherein the ester derivative of hydroxyalkylalkylcellulose is hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate. The polymer (ii) is one or more polymers selected from the group consisting of alkylene-based polymers, copolymers thereof, and salts thereof,
A set according to any one of claims 1 to 7, wherein the alkylene-based polymer and copolymers thereof are selected from the group consisting of vinyl-based polymers, propylene-based polymers and butylene-based polymers, and copolymers thereof. Claim 10, wherein the vinyl-based polymer is a polymer containing one or more monomer units selected from the group consisting of vinyl alcohol, acrylic acid and its ester derivatives, methacrylic acid and its ester derivatives, and vinylpyrrolidone. set of. A set according to any one of the preceding claims, wherein said particles have a substantially uniform size. The set according to any one of claims 1 to 12, wherein the active ingredient is a low-molecular-weight compound. A set according to any one of the preceding claims, wherein the amount of active ingredient relative to the weight of the particles is 0.01-80% (wt). A set according to any one of the preceding claims, wherein the amount of active ingredient relative to the weight of the particles is 0.1-15% (wt). The set according to any one of claims 1 to 15, wherein said particles have a tissue permeation effect for the active ingredient. A set according to any one of claims 1 to 16, wherein the active ingredient is a pharmaceutical ingredient and the oral solid composition is a medicament. 18. Any one of claims 1-17, wherein the oral solid composition is a tablet, capsule, granule, powder, fine granule, dry syrup, cashew, pill, lozenge, troche, gum, chocolate, or gummy. described set.

Images